Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review
The DOI matches its Crossref record; 484 of the 491 references it cites were found in a registry or an index.
Abstract
Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus. Because many women with polycystic ovary syndrome (PCOS) are insulin resistant, metformin was introduced in clinical practice to treat these patients also. Moreover, metformin's effect has other targets beside its insulin-sensitizing action. The present review was aimed at describing all evidence-based and potential uses of metformin in PCOS patients. In particular, we will analyze the uses of metformin not only for the treatment of all PCOS-related disturbances such as menstrual disorders, anovulatory infertility, increased abortion, or complicated pregnancy risk, hyperandrogenism, endometrial, metabolic and cardiovascular abnormalities, but also for the prevention of the syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the beneficial effects of metformin are increasingly evident, especially when combined with lifestyle modifications, improving the pathogenetic mechanisms underlying PCOS, restoring ovarian function, and improving metabolic profile, especially insulin sensitivity and, unlike COCs, lipoprotein pattern [49].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [49]
In the citing paper
“Metformin has been used extensively in DM2, is the most studied in PCOS, and has the most reassuring safety profile. 222”
From Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline (2011) · cites this paper as [222]
Citations
Cites
4 retracted
Activation of the AMP-activated Protein Kinase by the Anti-diabetic Drug Metformin in Vivo
Zou, M.-H., Kirkpatrick, S. S., Davis, B. J., Nelson, J. S., Wiles, W. G., Schlattner, U., Neumann, D., Brownlee, M., Freeman, M. B., & Goldman, M. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404421200 · Cited by 478
RetractedClomiphene citrate for ovulation induction in women with oligo-amenorrhoea
Hughes, E. G., Collins, J. A., & Vandekerckhove, P. (1996) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000056 · Cited by 75
RetractedWei, Z., Cao, Y., Cong, L., Zhou, P., Zhang, Z., & Li, J. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.07.1385 · Cited by 37
RetractedKoçak, İ., & Üstün, C. (2006) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2006.00401.x · Cited by 24
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866
Research works printed but not linked: 5
- 2005, American Association of Clinical Endocrinologists position statements on metabolic and cardiovascular consequences of polycystic ovary syndrome., Endocr Pract, 11, 126
- Deaton, 1991, Hyperandrogenism and uterine bleeding., Infertil Reprod Med Clin North Am, 2, 561
- 1992, Recent advances in medically assisted conception., WHO Tech Rep Ser, 820, 1
- Sonntag, 2005, Metformin alters insulin signaling and viability of human granulosa cells., Fertil Steril, 84, 1173, 10.1016/j.fertnstert.2005.04.043 · DOI
- Koschinsky, 1988, Influence of metformin on vascular cell proliferation., Diabetes Metab, 14, 566
Cited by
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Polycystic ovary syndrome: etiology, pathogenesis and diagnosis
Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.217 · Cited by 1,488
“As first-step therapy for anovulation, no consistent evidence suggests that metformin is better than clomiphene citrate regarding cumulative ovulation, pregnancy or live-birth rates”
BackgroundThe Mammalian Ovary from Genesis to Revelation
Edson, M. A., Nagaraja, A. K., & Matzuk, M. M. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0012 · Cited by 820
“For a more extensive review of the pathophysiology and potential genes involved in polycystic ovarian syndrome, the reader is referred to previous work in this journal (272, 273).”
BackgroundPregnancy complications in women with polycystic ovary syndrome
Palomba, S., de Wilde, M. A., Falbo, A., Koster, M. P. H., La Sala, G. B., & Fauser, B. C. J. M. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv029 · Cited by 691
Self-citationEndometrial function in women with polycystic ovary syndrome: a comprehensive review
Palomba, S., Piltonen, T. T., & Giudice, L. C. (2021) · Human Reproduction Update · doi:10.1093/humupd/dmaa051 · Cited by 372
Self-citationAssessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline
Teede, H. J., Misso, M. L., Deeks, A. A., Moran, L. J., Stuckey, B. G. A., Wong, J. L. A., Norman, R. J., Costello, M. F., & Groups, O. B. O. T. G. D. (2011) · Medical Journal of Australia · doi:10.5694/mja11.10915 · Cited by 379
Regensteiner, J. G., Golden, S., Huebschmann, A. G., Barrett-Connor, E., Chang, A. Y., Chyun, D., Fox, C. S., Kim, C., Mehta, N., Reckelhoff, J. F., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000343 · Cited by 334
“However, metformin treatment may have direct and indirect effects on vascular function beyond insulin sensitivity.(190) Trying to attribute changes in vascular function to sex steroids with current data is difficult because oral contraceptive estrogen dose and varying progesterone components may be associated with wor…”
BackgroundArmanini, D., Boscaro, M., Bordin, L., & Sabbadin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084110 · Cited by 324
“However, the beneficial effects of metformin are increasingly evident, especially when combined with lifestyle modifications, improving the pathogenetic mechanisms underlying PCOS, restoring ovarian function, and improving metabolic profile, especially insulin sensitivity and, unlike COCs, lipoprotein pattern [49].”
BackgroundComplications and challenges associated with polycystic ovary syndrome: current perspectives
Palomba, S., Santagni, S., Falbo, A., & La Sala, G. B. (2015) · International Journal of Women's Health · doi:10.2147/ijwh.s70314 · Cited by 287
Self-citationRepositioning metformin for cancer prevention and treatment
Quinn, B. J., Kitagawa, H., Memmott, R. M., Gills, J. J., & Dennis, P. A. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.05.004 · Cited by 281
Exercise therapy in polycystic ovary syndrome: a systematic review
Harrison, C. L., Lombard, C. B., Moran, L. J., & Teede, H. J. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmq045 · Cited by 267
“Metformin is commonly used to improve IR in Type 2 diabetes and in PCOS also improves IR with clinical benefits; including improved ovulatory function (Harborne et al., 2005; Nestler, 2008; Palomba et al., 2009; Tang et al., 2010).”
BackgroundInfluentialDiamanti-Kandarakis, E., Christakou, C. D., Kandaraki, E., & Economou, F. N. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0733 · Cited by 247
Metformin and Other Biguanides in Oncology: Advancing the Research Agenda
Pollak, M. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0175 · Cited by 240
Marsh, K. A., Steinbeck, K. S., Atkinson, F. S., Petocz, P., & Brand-Miller, J. C. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29261 · Cited by 228
Polycystic Ovary Syndrome Is a Risk Factor for Type 2 Diabetes
Gambineri, A., Patton, L., Altieri, P., Pagotto, U., Pizzi, C., Manzoli, L., & Pasquali, R. (2012) · Diabetes · doi:10.2337/db11-1360 · Cited by 225
“In addition, considerable variability in the metabolic responses to metformin has been observed in women with PCOS, attributably to several potential factors such as different doses of the drug and genetic background (37), which were not considered in the current study.”
BackgroundMetformin attenuates ovarian cancer cell growth in an AMP‐kinase dispensable manner
Rattan, R., Giri, S., Hartmann, L. C., & Shridhar, V. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00954.x · Cited by 223
“Interestingly, metformin is commonly used in the treatment of polycystic ovary syndrome, a syndrome associated with increased risk of ovarian and endometrial cancers [9].”
BackgroundOvarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention
Nastri, C. O., Teixeira, D. M., Moroni, R. M., Leitão, V. M. S., & Martins, W. P. (2015) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.14684 · Cited by 207
Jensterle Sever, M., Kocjan, T., Pfeifer, M., Kravos, N. A., & Janez, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0797 · Cited by 175
The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target?
Lansdown, A., & Rees, D. A. (2012) · Clinical Endocrinology · doi:10.1111/cen.12003 · Cited by 165
Glintborg, D., & Andersen, M. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903247873 · Cited by 159
“Several studies supported that metformin treatment significantly increased ovulation rate and metformin treatment is widely used to increase fertility in PCOS [15,16].”
BackgroundInfluentialThe Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Drzewoski, J., & Hanefeld, M. (2021) · Pharmaceuticals · doi:10.3390/ph14020122 · Cited by 193
Endometrial Cancer: Is This a New Disease?
Moore, K. N., & BREWER, M. A. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175666 · Cited by 145
Cassina, M., Donà, M., Di Gianantonio, E., Litta, P., & Clementi, M. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu022 · Cited by 143
“Since it does not increase the insulin production, the risk of hypoglycemia is minimized (Palomba et al., 2009b).”
BackgroundJahan, S., Abid, A., Khalid, S., Afsar, T., Ain, Q. U., Shaheen, G., Almajwal, A. M., & Razak, S. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0400-5 · Cited by 160
“Metformin improves insulin sensitivity, impedes hepatic glucose production and decreases androgen synthesis by ovarian theca cells [10, 11].”
BackgroundNybacka, Å., Carlström, K., Ståhle, A., Nyrén, S., Hellström, P. M., & Hirschberg, A. L. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.006 · Cited by 138
Jin, J., Ma, Y., Tong, X., Yang, W., Dai, Y., Pan, Y., Ren, P., Liu, L., Fan, H., Zhang, Y., et al. (2020) · Human Reproduction · doi:10.1093/humrep/deaa077 · Cited by 148
Fruzzetti, F., Perini, D., Russo, M., Bucci, F., & Gadducci, A. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1236078 · Cited by 135
“metformin may be limited by gastrointestinal side effects [15,16].”
BackgroundPalomba, S., Falbo, A. I., Orio, F., & Zullo, F. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.08.087 · Cited by 147
Self-citationCostello, M. F., Misso, M. L., Balen, A., Boyle, J., Devoto, L., Garad, R. M., Hart, R., Johnson, L., Jordan, C., Legro, R. S., et al. (2019) · Human Reproduction Open · doi:10.1093/hropen/hoy021 · Cited by 122
Wu, R.-R., Jin, H., Gao, K., Twamley, E. W., Ou, J.-J., Shao, P., Wang, J., Guo, X.-F., Davis, J. M., Chan, P. K., et al. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11091432 · Cited by 120
The effects of old, new and emerging medicines on metabolic aberrations in PCOS
Bargiota, A., & Diamanti-Kandarakis, E. (2012) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018812437355 · Cited by 119
“Metformin also ameliorates lipid profile via various mechanisms [Diamanti-Kandarakis et al. 1998; Palomba et al. 2009; Viollet et al. 2006], and directly inhibits thecal androgen production [Attia, et al.”
BackgroundMethodInfluentialLambert, E. A., Teede, H., Sari, C. I., Jona, E., Shorakae, S., Woodington, K., Hemmes, R., Eikelis, N., Straznicky, N. E., De Courten, B., et al. (2015) · Clinical Endocrinology · doi:10.1111/cen.12803 · Cited by 112
Jensterle, M., Kravos, N. A., Pfeifer, M., Kocjan, T., & Janez, A. (2015) · Hormones · doi:10.1007/bf03401383 · Cited by 117
Lautatzis, M.-E., Goulis, D. G., & Vrontakis, M. (2013) · Metabolism · doi:10.1016/j.metabol.2013.06.006 · Cited by 113
High-Fat Diet Induces Significant Metabolic Disorders in a Mouse Model of Polycystic Ovary Syndrome1
Lai, H., Jia, X., Yu, Q., Zhang, C., Qiao, J., Guan, Y., & Kang, J. (2014) · Biology of Reproduction · doi:10.1095/biolreprod.114.120063 · Cited by 112
Palomba, S., Falbo, A., & La Sala, G. (2013) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12070 · Cited by 110
Self-citationGanie, M. A., Khurana, M. L., Nisar, S., Shah, P. A., Shah, Z. A., Kulshrestha, B., Gupta, N., Zargar, M. A., Wani, T. A., Mudasir, S., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1040 · Cited by 109
“Administration of metformin (1g/d) to women with PCOS in the present study increased menstrual cyclicity and hirsutism score, decreased serum total T levels, and improved insulin sensitivity at 3 and 6 months of therapy, which was similar to our earlier observations (10) and findings reported by other researchers (17,…”
Metformin in polycystic ovary syndrome
Diamanti‐Kandarakis, E., Economou, F., Palimeri, S., & Christakou, C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05679.x · Cited by 109
Gow, M. L., Ho, M., Burrows, T. L., Baur, L. A., Stewart, L., Hutchesson, M. J., Cowell, C. T., Collins, C. E., & Garnett, S. P. (2014) · Nutrition Reviews · doi:10.1111/nure.12111 · Cited by 105
Metformin Reverses Development of Pulmonary Hypertension via Aromatase Inhibition
Dean, A., Nilsen, M., Loughlin, L., Salt, I. P., & MacLean, M. R. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07353 · Cited by 105
“is hypothesized that an additional therapeutic mechanism of metformin may be aromatase inhibition.(26,27) Metformin”
BackgroundCan ovarian aging be delayed by pharmacological strategies?
Zhang, J., Chen, Q., Du, D., Wu, T., Wen, J., Wu, M., Zhang, Y., Yan, W., Zhou, S., Li, Y., et al. (2019) · Aging · doi:10.18632/aging.101784 · Cited by 108
Nyane, N. A., Tlaila, T. B., Malefane, T. G., Ndwandwe, D. E., & Owira, P. M. O. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.03.042 · Cited by 101
Goel, S. K., Singh, R. P., Singh, V., Singh, H., Kumari, P., Chopra, H., Sharma, R., Nepovimová, E., Vališ, M., Kuča, K., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1022739 · Cited by 129
Ovulation induction in polycystic ovary syndrome
Tanbo, T. G., Mellembakken, J. R., Bjercke, S., Ring, E., Åbyholm, T., & Fedorcsák, P. (2018) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.13395 · Cited by 124
Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540578 · Cited by 94
“MET has proven to reduce glucose absorption and hepatic glucose synthesis and increase insulin sensitivity by increasing peripheral glucose uptake with no significant direct effect on pancreatic insulin production [7, 34, 35].”
BackgroundPolycystic Ovary Syndrome in the Pediatric Population
Bremer, A. A. (2010) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0039 · Cited by 94
“Metformin inhibits hepatic glucose production and increases peripheral tissue insulin sensitivity,(247) and in women with PCOS, appears to improve insulin sensitivity, insulin and androgen levels, lipid parameters, and menstrual cyclicity.(245,246,248) Moreover, it is effective in reducing the incidence of diabetes in…”
Pasquali, R., Gambineri, A., Cavazza, C., Ibarra Gasparini, D., Ciampaglia, W., Cognigni, G. E., & Pagotto, U. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0692 · Cited by 95
Jensterle, M., Kravos, N. A., Goričar, K., & Janez, A. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0155-9 · Cited by 93
“Metformin alone has well known beneficial metabolic and gynecological effects in this population that are mediated through improvement of IR and via direct action at the ovarian level beyond weight reduction [13].”
BackgroundWen, Q., Hu, M., Lai, M., Li, J., Hu, Z., Quan, K., Liu, J., Liu, H., Meng, Y., Wang, S., et al. (2022) · Human Reproduction · doi:10.1093/humrep/deab272 · Cited by 93
“Metformin is commonly prescribed for improving the metabolic complications and reproductive dysfunctions in women with PCOS and IR (Palomba et al. , 2009).”
Roland, A. V., & Moenter, S. M. (2011) · Endocrinology · doi:10.1210/en.2010-0823 · Cited by 92
Palomba, S., Falbo, A. I., Carrillo, L. I. V., Villani, M. T., Orio, F., Russo, T., Cello, A. D., Cappiello, F., Capasso, S., Tolino, A., et al. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.09.020 · Cited by 101
Self-citationAdak, T., Samadi, A., Ünal, A. Z., & Sabuncuoğlu, S. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.12.023 · Cited by 91
“However, some researchers have found that OCs are much more effective in terms of in regulating menstrual cycles than MET (Palomba et al., 2009).”
BackgroundMethodInfluentialGlintborg, D., Altinok, M. L., Mumm, H., Hermann, A. P., Ravn, P., & Andersen, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1135 · Cited by 88
Endometrial Abnormality in Women With Polycystic Ovary Syndrome
Shang, K., Jia, X., Qiao, J., Kang, J., & Guan, Y. (2012) · Reproductive Sciences · doi:10.1177/1933719111430993 · Cited by 93
“Considerable evidence has now shown the benefit of metformin treatment in patients with PCOS, including the reduction in hyperinsulinemia, insulin resistance, and hyperandrogenemia, improvement in ovulatory function, and also the beneficial effects on the endometrium.(89,90) Additionally, it was reported that metformi…”
BackgroundBiguanides: Species with versatile therapeutic applications
Kathuria, D., Raul, A. D., Wanjari, P. J., & Bharatam, P. V. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113378 · Cited by 96
The use of metformin in women with polycystic ovary syndrome: an updated review
Notaro, A. L. G., & Neto, F. T. L. (2022) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-022-02429-9 · Cited by 83
“As strategies for decreasing AEs, prolonged-release presentations should be preferred, the medication should be taken on an empty stomach, and the dose should be scaled up to the maximum dose, usually 2000 mg/day, over a period of 4 to 6 weeks [29].”
BackgroundPolycystic Ovary Syndrome, Obesity and Reproductive Implications
Hirschberg, A. L. (2009) · Women's Health · doi:10.2217/whe.09.39 · Cited by 83
“Metformin is a biguanide that inhibits the production of hepatic glucose, thereby decreasing insulin secretion, and enhances insulin sensitivity in peripheral tissues [83].”
BackgroundInfluentialDehydroepiandrosterone induces ovarian and uterine hyperfibrosis in female rats
Zhang, X., Zhang, C., Shen, S., Xia, Y., Yi, L., Gao, Q., & Wang, Y. (2013) · Human Reproduction · doi:10.1093/humrep/det341 · Cited by 89
“For Permissions, please email: journals.permissions@oup.com Human Reproduction, Vol.28, No.11 pp. 3074–3085, 2013 Advanced Access publication on August 26, 2013 doi:10.1093/humrep/det341 Downloaded from https://academic.oup.com/humrep/article-abstract/28/11/3074/629495 by guest on 30 July 2018”
BackgroundMethodInfluentialMetformin: The hidden chronicles of a magic drug
Mahmood, K., Naeem, M., & Rahimnajjad, N. A. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2012.10.011 · Cited by 87
“So far lactic acidosis does have an association with metformin use but the benefit of usage outweighs this minimal disadvantage of lactic acidosis [10,11].”
BackgroundPalomba, S., Falbo, A. I., Giallauria, F., Russo, T., Tolino, A., Zullo, F., Colao, A. A. L., & Orio, F. (2009) · Diabetes Care · doi:10.2337/dc09-1516 · Cited by 88
“The acute effect of metformin on insulin sensitivity could either increase serum Hcy levels directly or induce malabsorption of vitamin B12 indirectly (7).”
BackgroundSelf-citationPalomba, S., Falbo, A., & La Sala, G. B. (2014) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-12-3 · Cited by 78
“Metformin, an insulin sensitizer widely used for treating type-2 diabetes mellitus, is employed in patients with polycystic ovary syndrome (PCOS) in light of the scientific data showing the pivotal role of insulin resistance in the pathogenesis of the syndrome, and of its beneficial effects on metabolism and ovulatory…”
BackgroundSelf-citationWang, T., Zhang, J., Hu, M., Zhang, Y., Cui, P., Li, X., Li, J., Vestin, E., Brännström, M., Shao, R., et al. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.31425 · Cited by 81
“Although metformin is a promising drug for treating PCOS patients with endometrial hyperplasia and carcinoma [34, 35], the molecular and functional metformin-induced alterations in the uterus under PCOS conditions have only been studied to a limited extent [36].”
BackgroundMeyer-Bahlburg, H. F. L., Dolezal, C., Haggerty, R., Silverman, M., & New, M. I. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0789 · Cited by 76
Polycystic ovary syndrome: A review for dermatologists
Housman, E., & Reynolds, R. V. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.05.007 · Cited by 96
Shpakov, A. O. (2021) · Pharmaceuticals · doi:10.3390/ph14010042 · Cited by 91
Carvajal, R., Rosas, C., Kohan, K., Gabler, F., Vantman, D., Romero, C., & Vega, M. (2013) · Human Reproduction · doi:10.1093/humrep/det116 · Cited by 74
Approach to the Girl with Early Onset of Pubic Hair
Oberfield, S. E., Sopher, A. B., & Gerken, A. T. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0225 · Cited by 73
“A, 4-Androstenedione; BMI, body mass index; CAH, congenital adrenal hyperplasia; CPP, central precocious puberty; DEXA, dual-energy x-ray absorptiometry; DHEA, dehydroepiandrosterone; DHEAS, DHEA sulfate; FGIR, fasting glucose-toinsulin ratio; hCG, human chorionic gonadotropin; 3 HSD2, 3 -hydroxysteroid dehydrogenase…”
BackgroundInfluentialModulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients
Genazzani, A. D., Santagni, S., Rattighieri, E., Chierchia, E., Despini, G., Marini, G., Prati, A., & Simoncini, T. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2014.897321 · Cited by 73
“determination of the best and most appropriate treatment to administer to PCOS patients [5,6], and some International Societies have clearly indicated the importance of evaluating the”
BackgroundChang, E. M., Han, J. E., Seok, H. H., Lee, D. R., Yoon, T. K., & Lee, W. S. (2013) · Clinical Endocrinology · doi:10.1111/cen.12099 · Cited by 86
Agrawal, A., Mahey, R., Kachhawa, G., Khadgawat, R., Vanamail, P., & Kriplani, A. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1549656 · Cited by 70
“the treatment of PCOS [8,9], the focus on myo-inositol is comparatively recent [10].”
BackgroundRotondi, M., Cappelli, C., Magri, F., Botta, R., Dionisio, R., Iacobello, C., De Cata, P., Nappi, R. E., Castellano, M., & Chiovato, L. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04042.x · Cited by 69
Ontogeny of polycystic ovary syndrome and insulin resistance in utero and early childhood
Abbott, D. H., & Bacha, F. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.05.023 · Cited by 67
Monastra, G., Unfer, V., Harrath, A. H., & Bizzarri, M. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1247797 · Cited by 67
“Metformin reduces glycemia levels leading consequently to decreased ovarian androgen production, and reduced circulating androgen levels [38].”
BackgroundPalomba, S., Falbo, A., Russo, T., Orio, F., Tolino, A., & Zullo, F. (2010) · Human Reproduction · doi:10.1093/humrep/dep466 · Cited by 67
“…on the regulation of glucose metabolism by insulin (Palomba et al., 2009a), and indices of insulin resistance are strong predictors of the efficacy of metformin therapy (Palomba et al., 2009b), which suggests that the drug could act to induce ovulation as a result of the improved metabolic control.”
InfluentialSelf-citationShao, R., Li, X., Feng, Y., Lin, J.-F., & Billig, H. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-33-41 · Cited by 71
“These positive systemic effects appear to be mediated by decreased circulating insulin levels, increased tissue-specific insulin sensitivity, and reduction of ovarian androgen biosynthesis [26,30].”
BackgroundZhang, S., Tu, H., Yao, J., Le, J., Jiang, Z., Tang, Q., Zhang, R., Huo, P., & Lei, X. (2020) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-020-00613-z · Cited by 70
“The function of metformin is commonly described for the modulation of insulin sensitivity and glucose metabolism in PCOS women [16].”
BackgroundCampagnoli, C., Pasanisi, P., Abbà, C., Ambroggio, S., Biglia, N., Brucato, T., Colombero, R., Danese, S., Donadio, M., Venturelli, E., et al. (2012) · Clinical Breast Cancer · doi:10.1016/j.clbc.2012.03.004 · Cited by 68
Zheng, Y., Wang, X.-H., Lai, M.-H., Yao, H., Liu, H., & Ma, H. (2013) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2012.0429 · Cited by 71
MANAGEMENT OF ENDOCRINE DISEASE: Morbidity in polycystic ovary syndrome
Glintborg, D., & Andersen, M. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0373 · Cited by 63
Ovarian drilling for surgical treatment of polycystic ovarian syndrome: a comprehensive review
Fernandez, H., Morin-Surroca, M., Torre, A., Faivre, E., Deffieux, X., & Gervaise, A. (2011) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2011.03.013 · Cited by 66
Progesterone administration for luteal phase deficiency in human reproduction: an old or new issue?
Palomba, S., Santagni, S., & Sala, G. B. L. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0205-8 · Cited by 70
“…to improvements in the systemic hormonal and/or metabolic environments [51], as shown by the analysis of follicular fluid that seemed to confirm that metformin acts directly on the ovary, improving local levels of androgens, ovarian insulin resistance and the levels of several growth factors [50].”
Self-citationPalomba, S., Falbo, A., & Zullo, F. (2009) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328332d188 · Cited by 61
Self-citationPeng, F., Hu, Y., Peng, S., Zeng, N., & Shi, L. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2034933 · Cited by 70
“MTF works by improving the insulin sensitivity, blocks the production of hepatic glucose and suppresses the synthesis of androgen by ovarian cells [10,11].”
BackgroundMedical management of metabolic dysfunction in PCOS
Duleba, A. J. (2012) · Steroids · doi:10.1016/j.steroids.2011.11.014 · Cited by 60
“The primary mechanism of action of metformin is believed to be related to reduction of hepatic gluconeogenesis [7,8].”
BackgroundLi, X., Guo, Y.-R., Lin, J.-F., Feng, Y., Billig, H., & Shao, R. (2014) · Journal of Cancer · doi:10.7150/jca.8009 · Cited by 64
“Second, the most commonly described function of metformin is the modulation of insulin sensitivity and glucose metabolism in PCOS women [37].”
BackgroundZhang, J., Xing, C., Cheng, X., & He, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1003238 · Cited by 73
Palomba, S., Falbo, A., Russo, T., Battista, L., Tolino, A., Orio, F., & Zullo, F. (2010) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2010.02525.x · Cited by 59
Self-citationGoodarzi, M. O., Louwers, Y. V., Taylor, K. D., Jones, M. R., Cui, J., Kwon, S., Chen, Y.-D. I., Guo, X., Stolk, L., Uitterlinden, A. G., et al. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.01.015 · Cited by 59
“The fact that insulin-sensitizing agents ameliorate features of PCOS points to insulin resistance as a key pathophysiologic factor (2).”
BackgroundMetformin Decreases Circulating Androgen and Estrogen Levels in Nondiabetic Women With Breast Cancer
Campagnoli, C., Berrino, F., Venturelli, E., Abbà, C., Biglia, N., Brucato, T., Cogliati, P., Danese, S., Donadio, M., Zito, G., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.08.012 · Cited by 61
Gerosuppressant Metformin: less is more
Menendez, J. A., Cufí, S., Oliveras-Ferraros, C., Vellon, L., Joven, J., & Vazquez-Martin, A. (2011) · Aging · doi:10.18632/aging.100316 · Cited by 58
“Metformin is known to delay premature onset of the menstrual cycle in girls while restoring ovulations in women with premature menopause [44, 45].”
BackgroundCurrent and experimental drug therapy for the treatment of polycystic ovarian syndrome
Corte, L. D., Foreste, V., Barra, F., Gustavino, C., Alessandri, F., Centurioni, M. G., Ferrero, S., Bifulco, G., & Giampaolino, P. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1781815 · Cited by 71
Palomba, S., Costanzi, F., Nelson, S. M., Caserta, D., & Humaidan, P. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01113-6 · Cited by 71
“These include insulin-sensitizing actions with reductions in insulin and IGF-1 level, anti-inflammatory effects with reductions in serum VEGF levels, and anti-androgenic effect with reductions in intraovarian androgen levels and restoration of a normal FSH sensitivity of the granulosa cell [69].”
BackgroundSelf-citationMalik, S., Saeed, S., Saleem, A., Khan, M. I., Khan, A., & Akhtar, M. F. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1294406 · Cited by 78
New guidelines for the diagnosis and treatment of PCOS
Orio, F., & Palomba, S. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.248 · Cited by 66
Self-citationReproductive neuroendocrine dysfunction in polycystic ovary syndrome: Insight from animal models
Roland, A. V., & Moenter, S. M. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.04.002 · Cited by 57
“In women with PCOS, metformin reduces insulin and androgen levels and improves menstrual cyclicity (Palomba et al., 2009).”
BackgroundHyperinsulinaemic androgen excess in adolescent girls
Ibáñez, L., Ong, K. K., López-Bermejo, A., Dunger, D. B., & de Zegher, F. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.58 · Cited by 56
JENSTERLE, M., GORICAR, K., & JANEZ, A. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3081 · Cited by 56
Zhang, Y., Wu, L., Li, T. C., Wang, C. C., Zhang, T., & Chung, J. P. W. (2022) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-022-00931-4 · Cited by 61
“Considering the prevalence of insulin resistance in women with PCOS, metformin was proposed as one of the treatments for PCOS [3].”
Background
Metadata
- Authors
- Palomba, S., Falbo, A., Zullo, F., & Orio, F.
- Affiliations
- Magna Graecia University (IT)
- Parthenope University of Naples (IT)
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2008-12-04
- Volume
- 30
- Issue
- 1
- Pages
- 1-50
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2160472557
- Cited by
- 426
- References
- 491
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 20 · 2023: 28 · 2022: 25 · 2021: 18 · 2020: 15 · 2019: 19 · 2018: 19 · 2017: 15 · 2016: 18 · 2015: 26 · 2014: 37 · 2013: 40 · 2012: 33
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutial research information system (Parthenope University of Naples) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- metformin, polycystic ovary syndrome, insulin sensitization, insulin resistance, menstrual disorders, anovulatory infertility, pregnancy complications, hyperandrogenism, endometrial abnormalities, cardiovascular risk, PCOS prevention, type 2 diabetes
- MeSH terms
- Anovulation, Cardiovascular Diseases, Endometrium, Female, Humans, Hypoglycemic Agents, Menstruation Disturbances, Metformin, Obesity, Polycystic Ovary Syndrome, Pregnancy, Pregnancy Complications, Quality of Life, Endometrial Neoplasms, Hyperandrogenism, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.